FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
CO:07:5 | Enhanced fibroblast signatures in females with early rheumatoid arthritis highlights a potential basis for poorer treatment outcomes Benedetta Monosi1, James Perera2, Alessandra Nerviani2|3, Maria Sole Chimenti1, Felice Rivellese2|3, Costantino Pitzalis2|3|4. | 1Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; 2Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, UK; 3Barts Health NHS Trust and Barts Biomedical Research Centre, National Institute for Health and Care Research, London, UK; 4Department of Biomedical Sciences Humanitas University and IRCCS Humanitas Research Hospital, Milano, Italy
160 -
PO:37:258 | Neutrophil and eosinophil extracellular traps in eosinophilic granulomatosis with polyangiitis: phenotype-based characterization and response to mepolizumab Michele Moretti1, Francesco Ferro2, Francesco Pisani1, Elisa Ferrigno1, Gaetano La Rocca1, Federica Di Cianni3, Rosaria Talarico2, Marta Mosca1, Chiara Baldini1, Ilaria Puxeddu1. | 1University of Pisa - Department of Clinical and Experimental Medicine, Pisa, Italy; 2Azienda Ospedaliero Universitaria Pisana - Rheumatology Unit, Pisa, Italy; 3University of Siena, Siena, Italy.
131 -
PO:03:044 | Impact of Inflammatory Bowel Disease on Clinical Phenotype and Treatment Response in Patients with Psoriatic Arthritis Maria Morrone1, Maria Giannotta1, Vincenzo Venerito1, Greta Giulia Dipietrangelo1, Stefano Stano1, Florenzo Iannone1, Giuseppe Lopalco1 | 1Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J University of Bari, Bari, Italy
28 -
PO:16:234 | Differential efficacy of induction treatments for lupus nephritis at onset and relapses: an observational study Giuseppe Alvise Ramirez1|2, Gabriele D Gallina1, Chiara Calabrese1|2, Serena Nannipieri1|2, Marta Calatroni3|4, Francesco Reggiani3|4, Giovanni Benanti1, Enrica Paola Bozzolo1, Raffaele Ceniccola2, Luca Moroni1|2, Marco Matucci-Cerinic1|2, Gabriella Moroni3|4, Lorenzo Dagna1|2 | 1IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases Milan, Italy; 2Vita- Salute San Raffaele University Milan, Italy; 3IRCCS Humanitas Research Hospital, Nephrology and Dialysis Division Rozzano, Milan, Italy; 4Humanitas University, Department of Biomedical Sciences Rozzano, Milan, Italy
28 -
Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study
2057PDF: 998IL RUOLO DEI LINFOCITI TH9 NELL'ARTRITE REUMATOIDE E NELLA RISPOSTA AL TRATTAMENTO CON INFLIXIMAB.: 607 -
PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse1, Marta Mosca2, David A Isenberg3, Joan T Merrill4, Thomas Dörner5, Michelle Petri6, Edward M Vital7|8, Eric F Morand9, Teri Jimenez10, Stephen Brookes11, Janine Gaiha-Rohrbach12, Christophe Martin13, Annette Nelde14, Christian Stach15 | 1Duke University - Division of Rheumatology and Immunology Durham, USA; 2University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; 3University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; 4Oklahoma Medical Research Foundation Oklahoma City, USA; 5Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; 6Johns Hopkins University School of Medicine Baltimore, USA; 7University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; 9Monash University - Centre for Inflammatory Diseases Melbourne, Australia; 10UCB Raleigh, USA; 11Biogen Maidenhead, United Kingdom; 12Biogen Cambridge, USA; 13UCB Slough, United Kingdom; 14Biogen Baar, Switzerland; 15UCB Monheim am Rhein, Germany
40 -
CO:01:1 | Efficacy and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study of 115 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Veronica Batani1, Jasmin Mahajne1, Lorenzo Dagna1, Emanuel Della Torre1. | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale San Raffaele, Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University, Munich, Germany
271 -
PO:04:046 | Achieving Early Clinical Response was Associated with Cumulative Benefits on Disease Impact up to 2 Years in Patients with Active Psoriatic Arthritis Treated with Bimekizumab William Tillett1|2, Joseph F Merola3, Iain B Mcinnes4, Kenneth B Gordon5, Richard B Warren6, Patrick Healy7, Jérémy Lambert8, Heather Edens9, Barbara Ink10, Paola Volpe11, Laure Gossec12 | 1Royal National Hospital of Rheumatic Diseases Bath, United Kingdom; 2Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath Bath, United Kingdom; 3Department of Dermatology and Department of Medicine, Division of Rheumatology, Utah Southwestern Medical Center Dallas, USA; 4College of Medical Veterinary and Life Sciences, University of Glasgow Glasgow, United Kingdom; 5Department of Dermatology, Medical College of Wisconsin Milwaukee, USA; 6Northern Care Alliance, NHS Foundation Trust and Manchester Academic Health Science Centre, University of Manchester Manchester, United Kingdom; 7UCB Morrisville, USA; 8UCB Colombes, France; 9UCB Smyrna, USA; 10UCB Slough, United Kingdom; 11UOC Reumatologia, P.O. Spirito Santo Pescara, Italy; 12Sorbonne Universite and Pitie-Salpetriere Hospital Paris, France
23 -
CO:10:3 | Clinical response to JAK inhibitors or non-TNFi-targeted biologicals according to synovial tissue characteristics in patients with difficult-to-treat rheumatoid arthritis Mariangela Salvato1, Alessandro Giollo1, Francesca Frizzera1, Kiren Khalid1, Lorenzo Di Luozzo1, Maria Capita1, Marianna Tamussin1, Carlo Garaffoni2, Marny Fedrigo3, Annalisa Angelini3, Ettore Silvagni2, Andrea Doria1. | 1Rheumatology Unit, Department of Medicine - DIMED, University of Padova; 2Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna; 3Cardiovascular Pathology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Italy
141 -
PO:22:038 | Recurrent Pneumonias and Persistent Inflammation in VEXAS Syndrome: The Role of BAL in Differential Diagnosis Francesco Ghellere1, Bernardo D'Onofrio1, Maria Chiara Ditto1, Salvatore Panaro1, Francesca Piccione1|2, Giacomo Tanti1, Enrico Fusaro1, Simone Parisi1 | 1SC Reumatologia, Città della Salute e della Scienza Torino, Italy; 2Fondazione Ricerca Molinette Torino, Italy
17 -
PO:07:102 | Predicting success with baricitinib in rheumatoid arthritis: efficacy across ages and serological profiles Daniele Lini1, Matteo Colina2, Romina Andracco3, Francesca Ometto4, Viviana Ravagnani5, Alberto Lo Gullo6, Simone Parisi7, Antonella Farina8, Patrizia Del Medico9, Marino Paroli10, Olga Addimanda1, Alessandra Bezzi11, Federica Lumetti12, Aldo Biagio Molica Colella13, Davide Murgia14, Maddalena Larosa15, Aurora Ianniello16, Elena Bravi17, Marta Priora18, Palma Scolieri19, Alessandro Volpe20. | 1Azienda Unità Sanitaria Locale di Bologna -- Policlinico S.Orsola- Azienda Ospedaliera Universitaria-IRCCS di Bologna, Bologna; 2Rheumatology Service. Department of Medicine and Oncology, Ospedale Santa Maria della Scaletta, Imola; 3Imperia Hospital, Internal Medicine Unit, Rheumatology outpatient clinic, Imperia; 4Azienda ULSS 6 Euganea, Rheumatology Outpatient Clinic, Padova; 5Santa Chiara Hospital APSS Trento, Rheumatology Unit, Trento; 6ARNAS Garibaldi di Catania, Rheumatology Unit, Catania; 7Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Rheumatology Department, Torino; 8Ospedale A. Murri di Fermo, Internal Medicine Unit, Rheumatology outpatient clinic, Fermo; 9Civitanova Marche Hospital, Rheumatology outpatient clinic - Internal Medicine Unit, Civitanova Marche; 10Sapienza University of Rome, Polo Pontino, Department of Clinical, Anesthesiological and Cardiovascular Sciences, Latina; 11ASL Romagna Rimini, Internal Medicine and Rheumatology Unit, Rimini; 12Azienda USL of Modena and University Hospital Policlinico di Modena, Rheumatology Unit, Modena; 13Rheumatology Unit, Azienda Ospedaliera Papardo, Messina; 14ASL VC Ospedale S. Andrea, Unit of Rheumatology, Vercelli; 15Azienda Sanitaria Locale 3 Genova, Division of Rheumatology - Medical Specialties Department, Genova; 16ASL Novara, Rheumatology Outpatient Unit, Novara; 17Ospedale G. Da Saliceto, Rheumatology Unit, Piacenza; 18ASL CN1, Rheumatology Day Hospital and outpatient clinic, Mondovì (CN); 19Nuovo Regina Margherita Hospital, Department of Medical Specialties, Roma; 20IRCCS Sacro Cuore Don Calabria Hospital, Unit of Rheumatology, Negrar, Italy.
126 -
PO:33:197 | Systemic sclerosis and endothelial dysfunction: the passive leg movement technique in the assessment of no-mediated vascular impairment Silvia Guella1, Giovanni Baldassarre3, Alessandro Gratton2|3, Lucrezia Zuccarelli3, Elena Treppo2, Emma Di Poi2, Bruno Grassi3, Luca Quartuccio2|3 | 1SS Reumatologia-CMID Ospedale San Giovanni Bosco, Torino; 2Clinica di Reumatologia Ospedale Santa Maria della Misericordia, ASUFC, Udine; 3Dipartimento di Medicina, Università di Udine, Italy
138 -
PO:19:286 | Genetic testing reveals an unexpected case of mevalonate kinase deficiency in a 37-year-old patient with AA renal amyloidosis and good response to colchicine Francesca Crisafulli1, Paolo Airò2, Federica Mescia3, Gianmarco Lugli3, Gianfranco Savoldi4, Claudia Izzi3|5, Federico Alberici3, Marco Cattalini6, Franco Franceschini1, Micol Frassi2. | 1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy; 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, Brescia, Italy; 3U.O Nefrologia, ASST Spedali Civili di Brescia e Università degli Studi di Brescia, Brescia, Italy; 4Medical genetics Laboratory, Laboratory Department ASST Spedali Civili di Brescia, Brescia, Italy; 5Struttura Complessa di Genetica Clinica, ASST Spedali Civili di Brescia, Brescia, Italy; 6Pediatrics Clinic, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy.
142 -
PO:35:218 | Switching the dose of mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European retrospective multicentre real-world study Edoardo Biancalana1, Irene Mattioli1, Emanuele Chiara2, Danilo Malandrino1, Maria Canfora1, Palmerini Miki1, Maria Paola Lisi1, Michela Gasparotto3, Paola Tomietto3, Maria Letizia Urban1, Giacomo Bagni1, Elena Silvestri1, Alessandra Bettiol3, Augusto Vaglio3, Giacomo Emmi2 | 1Department of Experimental and Clinical Medicine, University of Florence Firenze, Italy; 2Department of Medical, Surgery and Health Sciences, University of Trieste Trieste, Italy; 3Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Trieste, Italy; 4Department of Biomedical, Experimental and Clinical Sciences Mario Serio, University of Florence Firenze, Italy
19 -
PO:26:092 | Early antiproteinuric effect of voclosporine in patients with lupus nephritis in real life setting: preliminary results from the VoRLiSS (Voclosporine in Real Life Setting Study) Aurora Di Gregorio1, Marta Calatroni2, Marco Allinovi3, Alessandra Bortoluzzi4, Giorgio Buscetta5, Rossella De Angelis6, Ginevra De Marchi7, Giacomo Emmi8, Pasquale Esposito9, Paride Fenaroli10, Micaela Fredi11, Giovanni Orsolini12, Giulia Pazzola13, Domenico Santoro14, Andrea Doria1, Gabriella Moroni2, Luca Iaccarino1 | 1Azienda Ospedaliera Universitaria Padova, Italy; 2Ospedale IRCCS Humanitas Milano, Italy; 3Azienda Ospedaliero Universitaria Careggi Firenze, Italy; 4Azienda Ospedaliero Universitaria di Ferrara, Italy; 5Policlinico Universitario Paolo Giaccone Palermo, Italy; 6Università Politecnica delle Marche Ancona, Italy; 7Università di Udine, Italy; 8Università di Trieste, Italy; 9Università di Genova, Italy; 10Unità di Nefrologia AUSL IRCCS di Reggio Emilia, Italy; 11Università di Brescia, Italy; 12Università di Verona Verona, Italy; 13Università di Reggio Emilia, Italy; 14Azienda Ospedaliera Universitaria G. Martino di Messina, Italy
29 -
CO:11:3 | Belimumab for lupus nephritis patients with poor kidney function: a post-hoc analysis of the bliss-ln trial Giacomo Emmi1|2, Ersilia Lucenteforte3, Giorgio Limoncella3, Emanuele Chiara1|2, Marta Calatroni4|5, Gabriella Moroni4|5 | 1Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy; 2Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; 3Department of Statistics, Informatics and Applications Giuseppe Parenti, University of Florence, Florence, Italy; 4Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; 5Nephrology and Dialysis Division, IRCCS Humanitas Research Hospital, Milan, Italy
15 -
PO:01:003 | Sex-based differences in 2 years treatment outcomes with b/ts-DMARDs in psoriatic arthritis: from real-world evidence to predictive modeling from the Gruppo Italiano Studio Early Arthritis (GISEA) prospective registry Simone Perniola1, Florenzo Iannone1, Francesco Paolo Cantatore2, Angelo Semeraro3, Leonardo Santo4, Roberto Gorla5, Alberto Cauli6, Roberto Felice Caporali7, Bruno Frediani8, Rosario Foti9, Fabrizio Conti10, Marco Sebastiani11, Maria Sole Chimenti12, Roberta Ramonda13, Fabiola Atzeni14, Maurizio Rossini15, Serena Bugatti16, Serena Guiducci17, Giovanni Lapadula1, Gianfranco Ferraccioli18, Francesca Romana Spinelli10, Elisa Gremese19. | 1Rheumatology Unit, DiMePReJ, University of Bari, Bari; 2Rheumatology Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria Policlinico Riuniti, Foggia; 3Rheumatology Unit, Martina Franca Hospital; 4Rheumatology Unit, ASL BT, P.O. Barletta; 5Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia; 6Rheumatology Unit, Department of Medical Science and Public Health, University of Cagliari, Monserrato (CA); 7Rheumatology Unit, Dipartimento di Reumatologia e Scienze Mediche, ASST PINI-CTO, University of Milano, Milano; 8Rheumatology Unit, Azienda Ospedaliero Universitaria Senese, Siena; 9Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania; 10Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and CV Sciences, Sapienza University of Rome, Roma; 11Rheumatology Unit, AUSL Piacenza, University of Parma, Parma; 12Rheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Roma; 13Rheumatology Unit, DIMED, University of Padua, Padova; 14Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina; 15Rheumatology Unit, Department of Medicine, University of Verona, Verona; 16Division of Rheumatology, Dept. of Internal Medicine and Therapy, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia; 17Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Firenze, Firenze; 18Department of Medicine, Catholic University of the Sacred Heart, Fondazione Policlinico Gemelli IRCCS, Roma; 19Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy
182 -
PO:29:131 | Early effect of auricular acupuncture on pain modulation in patients with fibromyalgia: findings from a real-life experience Benedetta Bianchi1, Edoardo Cipolletta1, Sonia Farah1, Fausto Salaffi1, Marco Di Carlo1 | 1Clinica Reumatologica, Università Politecnica delle Marche, ospedale Carlo Urbani Jesi, Ancona, Italy
29 -
PO:02:018 | After-SECs: clinical predictors of secukinumab retention in psoriatic arthritis patients with inadequate response to anti-tumor necrosis factor therapy Francesco Cristiano1, Davide Gaspare Patti1, Valentina Boni1, Stefano Di Murro1, Cesare Gavotti1, Roberta Masnata1, Giulia Calabrese2, Gerlando Natalello2, Giusy Peluso2, Augusta Ortolan1|2, Enrico De Lorenzis1|2, Maria Antonietta D'Agostino1|2. | 1Università Cattolica del Sacro Cuore, Roma, Italy; 2Divisione di Reumatologia ed Immunologia clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
144 -
PO:07:108 | Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study Enrico Marchetta1, Andrew Östör2|8, Eugen Feist3, Prodromos Sidiropoulos4, Jérôme Avouac5, Martin Rebella6|7, Rajaie Namas9, Erin Mcdearmon Blondell10, Ivan Lagunes10, Tianming Gao10, Tim Shaw10, Suzan Attar11 | 1AbbVie Srl Roma, Italy; 2Monash University and Emeritus Research, Melbourne, Victoria, Melbourne, Australia; 3Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Vogelsang Gommern, Germany; 4Faculty of Medicine, University of Crete, Heraklion, Heraklion, Greece; 5Service de Rhumatologie, Hôpital Cochin, AP HP Centre Université Paris Cité, Parigi, France; 6Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Montevideo, Uruguay; 7Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Montevideo, Uruguay; 8Australian National University, Camberra, Australia; 9Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, United Arab Emirates; 10AbbVie Inc., North Chicago, Illinois, United States of America Chicago, USA; 11King Abdulaziz University, Jeddah, Saudi Arabia
17 -
PO:15:212 | Anifrolumab induces a rapid improvement in joint inflammation in Systemic Lupus Erythematosus patients: an ultrasonographic study Valeria Moretti, Fulvia Ceccarelli, Claudia Ciancarella, Valerio Fiorilli, Francesca Romana Spinelli, Fabrizio Conti | Sapienza Università di Roma, Italy
12 -
PO:26:087 | Rituximab versus glucocorticoids for IgG4-related disease: a European retrospective multi-center study of 167 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Jasmin Mahajne1, Veronica Batani1, Lorenzo Dagna1, Emanuel Della-Torre1 | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale san Raffaele Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Stavanger, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich Germany
47 -
S02:5 | Combined anti-IL-5/IL-5r and dupilumab therapy in eosinophilic granulomatosis with polyangiitis: a European retrospective study Miriam Guerini1, Pavel Novikov2, Roberto Padoan3, Georgina Espigol Frigolé4, Jan Willem Cohen Tervaert5, Vincent Grobost6, Laurent Guilleminault7, Jan Walter Schroeder8, Bernhard Hellmich9, Joana Martins Martinho10, Camillo Ribi11, Matthieu Groh12, Benjamin Terrier13. | 1IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy; 2Sechenov University, Moscow, Russia; 3University of Padova, Padova, Italy; 4Hospital Clinic, University of Barcelona, Barcelona, Spain; 5University of Alberta, Edmonton, Canada; 6CHU Estaing Clermont-Ferrand France; 7Toulouse University Toulouse France; 8ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; 9Medius Kliniken Kirchheim-Teck Germany; 10ULS Santa Maria, Lisbon, Portugal; 11Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 12Hopital Foch, Suresnes, France; 13Service de Medecine interne, Hopital Cochin, AP-HP, Paris, France.
182 -
PO:05:066 | Atypical diagnosis and manifestation of spondyloarthritis: a case report Adele Del Giudice1, Filippo Crescentini2, Giorgia Citriniti2, Luca Cimino1|3, Carlo Salvarani1|2 | 1Department of Rheumatology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 2Department of Medicine, University of Melbourne at St Vincent's Hospital Melbourne, Australia; 3Department of Rheumatology, Division of Medicine, University College, London, UK
113 -
CO:01:2 | BAG3 in systemic sclerosis: possible therapeutic target and biomarker for pulmonary fibrosis Claudia Iannone1|2, Margot De Marco3, Antonina Minniti1, Paola Manzo3, Angela D'Ardia3, Antonia Falco3, Liberato Marzullo3, Angela Rosato3, Maria Caterina Turco3, Roberto Caporali1|2, Nicoletta Del Papa1|2. | 1ASST G. Pini-CTO. UOC Clinica Reumatologica, Milano; 2Department of Clinical Sciences and Community Health, University of Milano; 3Department of Medicine, Surgery and Dentistry Schola Medica Salernitana, Baronissi (SA), Italy
212 -
PO:08:113 | Shaping rheumatoid arthritis treatment: clinical and demographic drivers of tsDMARDs versus bDMARDs prescription post-EMA pronouncement on JAK inhibitors - insights from the AMBI-RA study Riccardo Bertola1, Beatrice Maranini1, Carlo Garaffoni1, Maria Pozzuto1, Anna Laura Riva Cambrino1, Alessandro Spinelli1, Letizia Mamprin1, Federico Agostini1, Martina Di Nunzio1, Marcello Govoni1, Alessandra Bortoluzzi1, Ettore Silvagni1 | 1Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Italy
153
